Cartesian Therapeutics, Inc. (RNAC)
(Real Time Quote from BATS)
$26.19 USD
+1.59 (6.46%)
Updated May 22, 2024 12:02 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RNAC 26.19 +1.59(6.46%)
Will RNAC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNAC
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for RNAC
Cartesian stock climbs 8% on FDA regenerative therapy designation
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian receives FDA RMAT designation for Descartes-08 for treatment of MG
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion